Home » Topics » BioWorld Science

BioWorld Science
RSS

OSI and Genentech sign new Tarceva agreements

June 18, 2004

Second phase III trial of phenserine for Alzheimer's disease

June 18, 2004

Sepracor resubmits Estorra NDA

June 18, 2004

FDA approves Rapinex powder for oral suspension 20 mg

June 18, 2004

Disappointing preliminary phase IIa results for NGD-2000-1 in RA

June 18, 2004

Clinical efficacy of a BAY-43-9006 combination regimen in advanced melanoma

June 18, 2004

Vasogen updates Celacade phase III program

June 18, 2004

Enzon strengthens pipeline during Q3 through Onco TCS addition

June 18, 2004

NCX-911 may benefit ED patients with dysfunctional endogenous NO production

June 18, 2004

Treatment options for restless legs syndrome

June 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...